Logo

Luminex

DiaSorin Q2 Revenues Rise 20 Percent on SARS-CoV-2 Testing Demand

DiaSorin posted Q2 molecular revenues of €69.4 million, up 23 percent year over year from €56.6 million.

DiaSorin Q1 Revenues Rise 53 Percent on SARS-CoV-2 Testing Demand

The company said that its Q1 revenue growth was driven in part by SARS-CoV-2 test revenues of €102.0 million, booked mainly in the US, Canada, and Europe.

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence
Premium

DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.

DiaSorin to Acquire Luminex for $1.8B

DiaSorin said that the transaction is expected to be immediately accretive to its earnings per share and result in cost synergies of about $55 million within three years.

Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

The firm said that with the addition of a target for SARS-CoV-2, its high-throughput NxTag syndromic respiratory panel includes 19 viral and two bacterial targets.

Feb 25, 2021

Luminex Shares Surge on Rumor of Acquisition by DiaSorin

Feb 19, 2021

Luminex Nabs $11.3M From BARDA to Develop Test for SARS-CoV-2, Flu, RSV

Feb 9, 2021

Luminex Moving Ahead With EUA Applications Despite Deprioritization of SARS-CoV-2 Test Submission
Premium

Feb 8, 2021

Luminex Q4 Revenues Rise 23 Percent; FDA Deprioritizes EUA Submission for COVID-19 Test

Jan 14, 2021

JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More

Jan 12, 2021

Luminex Preliminary Q4 Revenues Increase 23 Percent on MDx Strength

Nov 5, 2020

Luminex Q3 Revenues Rise 35 Percent on Coronavirus Testing Demand

Oct 7, 2020

Luminex Preliminary Q3 Revenues Rise 35 Percent on Pandemic-Related Demand

Sep 8, 2020

As Flu Season Nears, Dx Companies Shift Attention to Multiplex Tests for SARS-CoV-2, Influenza
Premium

Aug 27, 2020

As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit

Aug 5, 2020

Luminex Responds to FDA Warning Letter While Ramping SARS-CoV-2 Test Manufacturing
Premium

Aug 4, 2020

Luminex Q2 Revenues Rise 32 Percent on Pandemic-Related Sales

Jul 8, 2020

Luminex Preliminary Q2 Revenues Rise More Than 30 Percent on Pandemic-Related Sales

Jun 30, 2020

FDA Issues Warning Letter to Luminex

Jun 1, 2020

Fluidigm Leads May GenomeWeb Index on Early Detection SARS-Cov-2 Blood Test Collaboration Details

May 8, 2020

Luminex Prices $260M Senior Notes Offering

May 4, 2020

Luminex Q1 Revenues Rise 10 Percent

Apr 13, 2020

Coronavirus Tests From Seegene, DiaSorin, Others Get Health Canada Approval

Apr 6, 2020

Luminex Preliminary Q1 Revenues Rise 10 Percent

Apr 6, 2020

Luminex Receives FDA Emergency Use Authorization for Second SARS-CoV-2 Assay

Breaking News
The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.